Insulet (PODD) Total Non-Current Liabilities (2010 - 2026)
Insulet's (PODD) quarterly Total Non-Current Liabilities came in at $1.6 billion in Q1 2026, down 24.19% YoY from $2.1 billion in Q1 2025, and little changed on a QoQ basis from $1.6 billion in Q4 2025.
Insulet (PODD) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Insulet (PODD) has 17 years of Total Non-Current Liabilities data on file, last reported at $1.6 billion in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 24.19% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (down 24.19% YoY) and the FY2025 annual result came in at $1.6 billion, down 11.71% from the prior year.
- Total Non-Current Liabilities was little changed at $1.6 billion in Q1 2026, from $1.6 billion in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $2.1 billion in Q1 2025 to a low of $1.6 billion in Q3 2025.
- A 5-year average of $1.8 billion and a median of $1.8 billion in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Non-Current Liabilities climbed 29.78% — and 2026, when it decreased 24.19%.
- Tracing PODD's Total Non-Current Liabilities over 5 years: stood at $1.7 billion in 2022, then increased by 4.52% to $1.8 billion in 2023, then gained by 0.37% to $1.8 billion in 2024, then declined by 11.71% to $1.6 billion in 2025, then increased by 0.38% to $1.6 billion in 2026.
- The last three Total Non-Current Liabilities figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.49 Bn | 193.88 Bn | 7.27 Bn | - |
| 2 | Stryker | 127.80 Bn | 124.32 Bn | 4.50 Bn | 21.28 Bn |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn | 40.90 Bn |
| 4 | Boston Scientific | 73.58 Bn | 73.04 Bn | 3.85 Bn | 42.74 Bn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 2.57 Bn |
| 6 | Dexcom | 34.34 Bn | 32.39 Bn | 830.00 Mn | 3.68 Bn |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.66 Bn | 2.18 Bn | 23.89 Bn |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 9.07 Bn |
| 9 | Steris | 23.07 Bn | 22.59 Bn | 684.20 Mn | 3.44 Bn |
| 10 | Insulet | 10.34 Bn | 9.80 Bn | 562.60 Mn | 1.67 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.67 Bn |
| Mar 31, 2026 | 1.62 Bn |
| Dec 31, 2025 | 1.61 Bn |
| Sep 30, 2025 | 1.58 Bn |
| Jun 30, 2025 | 1.95 Bn |
| Mar 31, 2025 | 2.13 Bn |
| Dec 31, 2024 | 1.82 Bn |
| Sep 30, 2024 | 1.86 Bn |
| Jun 30, 2024 | 1.85 Bn |
| Mar 31, 2024 | 1.80 Bn |
| Dec 31, 2023 | 1.82 Bn |
| Sep 30, 2023 | 1.82 Bn |
| Jun 30, 2023 | 1.79 Bn |
| Mar 31, 2023 | 1.75 Bn |
| Dec 31, 2022 | 1.74 Bn |
| Sep 30, 2022 | 1.71 Bn |
| Jun 30, 2022 | 1.66 Bn |
| Mar 31, 2022 | 1.61 Bn |
| Dec 31, 2021 | 1.48 Bn |
| Sep 30, 2021 | 1.49 Bn |